全文获取类型
收费全文 | 2162篇 |
免费 | 255篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 170篇 |
妇产科学 | 26篇 |
基础医学 | 226篇 |
口腔科学 | 73篇 |
临床医学 | 204篇 |
内科学 | 654篇 |
皮肤病学 | 32篇 |
神经病学 | 118篇 |
特种医学 | 218篇 |
外科学 | 149篇 |
综合类 | 138篇 |
预防医学 | 184篇 |
眼科学 | 9篇 |
药学 | 101篇 |
中国医学 | 3篇 |
肿瘤学 | 153篇 |
出版年
2023年 | 21篇 |
2022年 | 17篇 |
2021年 | 31篇 |
2020年 | 28篇 |
2019年 | 14篇 |
2018年 | 30篇 |
2017年 | 46篇 |
2016年 | 50篇 |
2015年 | 43篇 |
2014年 | 77篇 |
2013年 | 93篇 |
2012年 | 65篇 |
2011年 | 62篇 |
2010年 | 84篇 |
2009年 | 97篇 |
2008年 | 79篇 |
2007年 | 120篇 |
2006年 | 94篇 |
2005年 | 75篇 |
2004年 | 80篇 |
2003年 | 45篇 |
2002年 | 38篇 |
2001年 | 70篇 |
2000年 | 49篇 |
1999年 | 46篇 |
1998年 | 88篇 |
1997年 | 73篇 |
1996年 | 73篇 |
1995年 | 57篇 |
1994年 | 59篇 |
1993年 | 50篇 |
1992年 | 42篇 |
1991年 | 31篇 |
1990年 | 50篇 |
1989年 | 51篇 |
1988年 | 56篇 |
1987年 | 41篇 |
1986年 | 57篇 |
1985年 | 42篇 |
1984年 | 29篇 |
1983年 | 25篇 |
1982年 | 23篇 |
1981年 | 13篇 |
1980年 | 17篇 |
1979年 | 16篇 |
1978年 | 15篇 |
1977年 | 12篇 |
1976年 | 18篇 |
1975年 | 19篇 |
1972年 | 12篇 |
排序方式: 共有2467条查询结果,搜索用时 15 毫秒
91.
Grundy SM 《Journal of the American College of Cardiology》2012,59(7):635-643
Pre-diabetes represents an elevation of plasma glucose above the normal range but below that of clinical diabetes. Pre-diabetes can be identified as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). The latter is detected by oral glucose tolerance testing. Both IFG and IGT are risk factors for type 2 diabetes, and risk is even greater when IFG and IGT occur together. Pre-diabetes commonly associates with the metabolic syndrome. Both in turn are closely associated with obesity. The mechanisms whereby obesity predisposes to pre-diabetes and metabolic syndrome are incompletely understood but likely have a common metabolic soil. Insulin resistance is a common factor; systemic inflammation engendered by obesity may be another. Pre-diabetes has only a minor impact on microvascular disease; glucose-lowering drugs can delay conversion to diabetes, but whether in the long run the drug approach will delay development of microvascular disease is in dispute. To date, the drug approach to prevention of microvascular disease starting with pre-diabetes has not been evaluated. Pre-diabetes carries some predictive power for macrovascular disease, but most of this association appears to be mediated through the metabolic syndrome. The preferred clinical approach to cardiovascular prevention is to treat all the metabolic risk factors. For both pre-diabetes and metabolic syndrome, the desirable approach is lifestyle intervention, especially weight reduction and physical activity. When drug therapy is contemplated and when the metabolic syndrome is present, the primary consideration is prevention of cardiovascular disease. The major targets are elevations of cholesterol and blood pressure. 相似文献
92.
Marwan SM Al-Nimer 《World journal of diabetes》2022,13(5):417-419
Hyperandrogenism and hyperinsulinemia have resulted from dysfunction of the theca cell of the ovary and adipose tissue and each one potentiates the other in patients with androgen excess disorders e.g., polycystic ovary disease and idiopathic hirsutism. Possible external and/or internal triggers can produce such cellular dysfunction. There is evidence that sodium valproate acts as a trigger of cellular dysfunction and produces both hyperinsulinemia and hyperandrogenism. Therefore, the elimination of these triggers can help the patients to recover from hyperinsulinemia, insulin resistance and hyperandrogenism. 相似文献
93.
94.
95.
SJ Smith CV Rahman PA Clarke AA Ritchie TW Gould JH Ward KM Shakesheff RG Grundy R Rahman 《Annals of the Royal College of Surgeons of England》2014,96(7):495-501
Introduction
The median survival of patients with glioblastoma multiforme (astrocytoma grade 4) remains less than 18 months despite radical surgery, radiotherapy and systemic chemotherapy. Surgical implantation of chemotherapy eluting wafers into the resection cavity has been shown to improve length of survival but the current licensed therapy has several drawbacks. This paper investigates in vivo efficacy of a novel drug eluting paste in glioblastoma.Methods
Poly(lactic-co-glycolic acid)/poly(ethylene glycol) (PLGA/PEG) self-sintering paste was loaded with the chemotherapeutic agent etoposide and delivered surgically into partially resected tumours in a flank murine glioblastoma xenograft model.Results
Surgical delivery of the paste was successful and practical, with no toxicity or surgical morbidity to the animals. The paste was retained in the tumour cavity, and preliminary results suggest a useful antitumour and antiangiogenic effect, particularly at higher doses. Bioluminescent imaging was not affected significantly by the presence of the paste in the tumour.Conclusions
Chemotherapy loaded PLGA/PEG paste seems to be a promising technology capable of delivering active drugs into partially resected tumours. The preliminary results of this study suggest efficacy with no toxicity and will lead to larger scale efficacy studies in orthotopic glioblastoma models. 相似文献96.
Ilias Nikolakopoulos MD James W. Choi MD Khaldoon Alaswad MD Jaikirshan J. Khatri MD Oleg Krestyaninov MD Dmitrii Khelimskii MD Robert W. Yeh MD PhD Farouc A. Jaffer MD PhD Catalin Toma MD Mitul Patel MD Ehtisham Mahmud MD Nicholas J. Lembo MD Manish Parikh MD Ajay J. Kirtane MD SM Ziad A. Ali MD Fotis Gkargkoulas MD Barry Uretsky MD Abdul M. Sheikh MD Evangelia Vemmou MD Iosif Xenogiannis MD Bavana V. Rangan BDS MPH Santiago Garcia MD Shuaib Abdullah MD Subhash Banerjee MD M. Nicholas Burke MD Emmanouil S. Brilakis MD PhD Dimitri Karmpaliotis MD PhD 《Catheterization and cardiovascular interventions》2021,97(4):658-667
97.
98.
Naghavi M Libby P Falk E Casscells SW Litovsky S Rumberger J Badimon JJ Stefanadis C Moreno P Pasterkamp G Fayad Z Stone PH Waxman S Raggi P Madjid M Zarrabi A Burke A Yuan C Fitzgerald PJ Siscovick DS de Korte CL Aikawa M Airaksinen KE Assmann G Becker CR Chesebro JH Farb A Galis ZS Jackson C Jang IK Koenig W Lodder RA March K Demirovic J Navab M Priori SG Rekhter MD Bahr R Grundy SM Mehran R Colombo A Boerwinkle E Ballantyne C Insull W Schwartz RS Vogel R Serruys PW Hansson GK Faxon DP Kaul S 《Circulation》2003,108(15):1772-1778
Atherosclerotic cardiovascular disease results in >19 million deaths annually, and coronary heart disease accounts for the majority of this toll. Despite major advances in treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. Available screening and diagnostic methods are insufficient to identify the victims before the event occurs. The recognition of the role of the vulnerable plaque has opened new avenues of opportunity in the field of cardiovascular medicine. This consensus document concludes the following. (1) Rupture-prone plaques are not the only vulnerable plaques. All types of atherosclerotic plaques with high likelihood of thrombotic complications and rapid progression should be considered as vulnerable plaques. We propose a classification for clinical as well as pathological evaluation of vulnerable plaques. (2) Vulnerable plaques are not the only culprit factors for the development of acute coronary syndromes, myocardial infarction, and sudden cardiac death. Vulnerable blood (prone to thrombosis) and vulnerable myocardium (prone to fatal arrhythmia) play an important role in the outcome. Therefore, the term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future. (3) A quantitative method for cumulative risk assessment of vulnerable patients needs to be developed that may include variables based on plaque, blood, and myocardial vulnerability. In Part I of this consensus document, we cover the new definition of vulnerable plaque and its relationship with vulnerable patients. Part II of this consensus document will focus on vulnerable blood and vulnerable myocardium and provide an outline of overall risk assessment of vulnerable patients. Parts I and II are meant to provide a general consensus and overviews the new field of vulnerable patient. Recently developed assays (eg, C-reactive protein), imaging techniques (eg, CT and MRI), noninvasive electrophysiological tests (for vulnerable myocardium), and emerging catheters (to localize and characterize vulnerable plaque) in combination with future genomic and proteomic techniques will guide us in the search for vulnerable patients. It will also lead to the development and deployment of new therapies and ultimately to reduce the incidence of acute coronary syndromes and sudden cardiac death. We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients. 相似文献
99.
Grundy SM Vega GL McGovern ME Tulloch BR Kendall DM Fitz-Patrick D Ganda OP Rosenson RS Buse JB Robertson DD Sheehan JP;Diabetes Multicenter Research Group 《Archives of internal medicine》2002,162(14):1568-1576
BACKGROUND: Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels. Niacin reduces concentrations of triglyceride-rich and small low-density lipoprotein particles while increasing high-density lipoprotein cholesterol levels. It also lowers levels of free fatty acids and lipoprotein(a). However, the use of niacin in patients with diabetes has been discouraged because high doses can worsen glycemic control. We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia. METHODS: During a 16-week, double-blind, placebo-controlled trial, 148 patients were randomized to placebo (n = 49) or 1000 (n = 45) or 1500 mg/d (n = 52) of ER niacin. Sixty-nine patients (47%) were also receiving concomitant therapy with statins. RESULTS: Dose-dependent increases in high-density lipoprotein cholesterol levels (+19% to +24% [P<.05] vs placebo for both niacin dosages) and reductions in triglyceride levels (-13% to -28% [P<.05] vs placebo for the 1500-mg ER niacin) were observed. Baseline and week 16 values for glycosylated hemoglobin levels were 7.13% and 7.11%, respectively, in the placebo group; 7.28% and 7.35%, respectively, in the 1000-mg ER niacin group (P=.16 vs placebo); and 7.2% and 7.5%, respectively, in the 1500-mg ER niacin group (P=.048 vs placebo). Four patients discontinued participation because of inadequate glucose control. Rates of adverse event rates other than flushing were similar for the niacin and placebo groups. Four patients discontinued participation owing to flushing (including 1 receiving placebo). No hepatotoxic effects or myopathy were observed. CONCLUSION: Low doses of ER niacin (1000 or 1500 mg/d) are a treatment option for dyslipidemia in patients with type 2 diabetes. 相似文献
100.
Weisdorf DJ; Verfaillie CM; Davies SM; Filipovich AH; Wagner JE Jr; Miller JS; Burroughs J; Ramsay NK; Kersey JH; McGlave PB 《Blood》1995,85(12):3452-3456
Delay in hematologic recovery after bone marrow transplantation (BMT) can extend and amplify the risks of infection and hemorrhage, compromise patients' survival, and increase the duration and cost of hospitalization. Because current studies suggest that granulocyte- macrophage (GM) colony-stimulating factor (CSF) may potentiate the sensitivity of hematopoietic progenitor cells to G-CSF, we performed a prospective, randomized trial comparing GM-CSF (250 micrograms/m2/d x 14 days) versus sequential GM-CSF x 7 days followed by G-CSF (5 micrograms/kg/d x 7 days) as treatment for primary or secondary graft failure after BMT. Eligibility criteria included failure to achieve a white blood cell (WBC) count > or = 100/microL by day +21 or > or = 300/microL by day +28, no absolute neutrophil count (ANC) > or = 200/microL by day +28, or secondary sustained neutropenia after initial engraftment. Forty-seven patients were enrolled: 23 received GM-CSF (10 unrelated, 8 related allogeneic, and 5 autologous), and 24 received GM- CSF followed by G-CSF (12 unrelated, 7 related allogeneic, and 5 autologous). For patients receiving GM-CSF alone, neutrophil recovery (ANC > or = 500/microL) occurred between 2 and 61 days (median, 8 days) after therapy, while those receiving GM-CSF+G-CSF recovered at a similar rate of 1 to 36 days (median, 6 days; P = .39). Recovery to red blood cell (RBC) transfusion independence was slow, occurring 6 to 250 days (median, 35 days) after enrollment with no significant difference between the two treatment groups (GM-CSF: median, 30 days; GM-CSF+G- CSF; median, 42 days; P = .24). Similarly, platelet transfusion independence was delayed until 4 to 249 days (median, 32 days) after enrollment, with no difference between the two treatment groups (GM- CSF: median, 28 days; GM-CSF+G-CSF: median, 42 days; P = .38). Recovery times were not different between patients with unrelated donors and those with related donors or autologous transplant recipients. Survival at 100 days after enrollment was superior after treatment with GM-CSF alone. Only 1 of 23 patients treated with GM-CSF died versus 7 of 24 treated with GM-CSF+G-CSF who died 16 to 84 days (median, 38 days) after enrollment, yielding Kaplan-Meier 100-day survival estimates of 96% +/- 8% for GM-CSF versus 71% +/- 18% for GM-CSF+G-CSF (P = .026). These data suggest that sequential growth factor therapy with GM-CSF followed by G-CSF offers no advantage over GM-CSF alone in accelerating trilineage hematopoiesis or preventing lethal complications in patients with poor graft function after BMT.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献